biorxiv.org· Niu, B., Deng, R., Xie, S., Gong, M., Yi, L., Zhang, Y., Xu, L., Yu, X., He, Y., Fu, W., Yang, Y., Li, X., Lin, X., Chen, M., Xie, Y., Chang, K. ·2026-10-16 08:00· 15 hours agoPickScore59

Metabolically encoded cell-surface glycoRNA remodeling enhances antitumor immunity

In brief

Glycolysis in breast cancer cells drives c-Myc-dependent repression of DTWD2, reducing acp3U attachment sites needed for RNA glycosylation and remodeling cell-surface glycoRNA. Loss of DTWD2-impaired glycoRNA weakens Toll-like receptor signaling activation, dendritic cell maturation and CD8+ T cell responses, while reversing aerobic glycolysis to restore glycoRNA improves the antitumor efficacy of PD-1 blockade. Lower glycoRNA abundance tracks with tumor stage and unfavorable prognosis, positioning glycoRNA as a regulator of antitumor immunity and a progression biomarker.

Why it matters

Identifies a metabolic reprogramming-to-RNA glycosylation route of immune escape that can be targeted to improve PD-1 blockade.

Source: biorxiv.org · biorxiv.org

#Preprint #Oncology #Immunotherapy